An international, randomized, double-blind, placebo-controlled, Phase III clinical trial led by scientists at Massachusetts General Hospital (MGH) demonstrated that adding the androgen-receptor inhibitor darolutamide to androgen-deprivation therapy and chemotherapy extended the survival of men with metastatic, hormone-sensitive prostate cancer.
Their study is published in the New England Journal of Medicine in a paper titled, “Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.”
